Feb 22, 2017 at 20:38 | Source: PTI
The Delhi High Court today told Swiss pharma major Roche that it "cannot hang on to" breast cancer drug Trastuzumab, innovated by it, for the rest of its life after having enjoyed the fruits of its patent.
Jan 25, 2017 at 11:02 | Source: CNBC-TV18
Attributing the strong show in Q3FY17 to robust performance in biologics, Biocon Chairperson and MD Kiran Mazumdar-Shaw told CNBC-TV18 that Biocon is well poised to be front-runner in biosimilars. The acceptance of biosimilar Trastuzumab by the USFDA is a huge milestone for Mylan and Biocon, she said.
Jan 12, 2017 at 09:44 | Source: Moneycontrol.com
Biocon shares touched a record high of Rs 1,049.50 on Thursday, up nearly 5 percent intraday after the US health regulator has accepted biosimilar application for its proposed cancer drug.
Jan 12, 2017 at 08:56 | Source: PTI
The proposed biosimilar trastuzumab is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace, the two companies said in a statement.
Jan 12, 2017 at 08:43 | Source: CNBC-TV18
Following US president-elect Donald Trumps explosive speech last night where he lambasted the domestic pharma companies for outsourcing work, pharma stocks are likely to be in limelight today.
Jan 12, 2017 at 08:21 | Source: Moneycontrol.com
Bengaluru-based biopharmaceutical firm Biocon on Wednesday said US drug regulator has accepted its partners Mylans biologics license application (BLA) for the proposed biosimilar of breast cancer drug Trastuzumab through the 351(k) pathway.
Dec 27, 2016 at 15:41 | Source: Moneycontrol.com
This study was the last major step of a multiple-phased programme to demonstrate that proposed biosimilar trastuzumab meets the criteria for equivalence in comparison to branded trastuzumab.
Dec 22, 2016 at 12:02 | Source: CNBC-TV18
Biocon is among the companies that gave a good performance in 2016 and the stock surged 80 percent this year. Speaking to CNBC-TV18, Kiran Mazumdar Shaw, CMD of the company, said the company has gained traction in many emerging markets with its biosimilars.
Dec 06, 2016 at 12:52 | Source: CNBC-TV18
Speaking to CNBC-TV18, Kiran Mazumdar Shaw, CMD of Biocon said huge opportunities exist for Biocon in the US biosimilars market.
Aug 26, 2016 at 09:13 | Source: CNBC-TV18
The European Medicines Agency (EMA) has accepted to review Mylan and Biocons application for a biosimilar called Trastuzumab, used for certain breast and gastric cancers.